Caricamento...
TIGIT as an emerging immune checkpoint
T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen‐presenting cells or tumour cells to down‐regulate T cel...
Salvato in:
| Pubblicato in: | Clin Exp Immunol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160651/ https://ncbi.nlm.nih.gov/pubmed/31828774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13407 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|